ImageneBio Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMA research report →
About the company
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
- CEO
- Kristin Yarema
- IPO
- 1998
- Employees
- 10
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $65.76M
- P/E
- -1.26
- P/S
- 0.00
- P/B
- 0.53
- EV/EBITDA
- 0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.20%
- ROIC
- -41.95%
- Revenue
- $800.00K · -77.14%
- Net Income
- $-45,349,000 · -24.01%
- EPS
- $-10.76 · -954.90%
- Op Income
- $-48,451,000
- FCF YoY
- -4.00%
- 52W High
- $18.00
- 52W Low
- $3.94
- 50D MA
- $5.74
- 200D MA
- $6.60
- Beta
- 0.73
- Avg Volume
- 346.16K
Get TickerSpark's AI analysis on IMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Wang Jonathan Jian | other | 15,600 |
| Jun 16, 26 | Stampacchia Otello | other | 15,600 |
| Jun 16, 26 | SLATTERY JOSEPH P | other | 15,600 |
| Jun 16, 26 | Bonita David P | other | 15,600 |
| Mar 20, 26 | Lally Robert B | other | 0 |
| Mar 20, 26 | Lally Robert B | other | 25,410 |
| Apr 16, 26 | Su Wei-guo | other | 0 |
| Apr 14, 26 | Bonita David P | buy | 384,689 |
| Apr 14, 26 | Bonita David P | buy | 336,603 |
| Apr 14, 26 | ORBIMED ADVISORS LLC | buy | 384,689 |
Our IMA coverage
Recent articles, reports, and earnings notes.
No research on IMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMA report →Similar companies
Peers in the same neighborhood.